Cognitive impairment in schizophrenia: A review of developmental and genetic models, and pro-cognitive profile of the optimised D3 > D2 antagonist, S33138

Therapie

Volumn 63, Issue 3, 2008, Pages 187-229

  Millan, Mark J ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Attention; Clozapine; Cognition; D3 receptor; Dopamine; Schizophrenia

Indexed keywords

ACETYLCHOLINE; CALCINEURIN; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DEXTRO AMINO ACID OXIDASE; DISRUPTED IN SCHIZOPHRENIA 1; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GLUTATHIONE; HALOPERIDOL; METABOTROPIC RECEPTOR 5; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NICOTINIC RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; OLANZAPINE; PHOSPHODIESTERASE IV; PROLACTIN; PROLINE DEHYDROGENASE; PROTEIN HOMER 1; PROTEIN KINASE B; QUETIAPINE; RGS4 PROTEIN; S 33138; SCOPOLAMINE; STABLE TUBULE ONLY POLYPEPTIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NPAS 3; UNCLASSIFIED DRUG; ACETANILIDE DERIVATIVE; BENZOPYRAN DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; N (4 (2 (8 CYANO 1,3A,4,9B TETRAHYDRO(1)BENZOPYRANO(3,4 C)PYRROL 2(3H) YL)ETHYL)PHENYL)ACETAMIDE; N-(4-(2-(8-CYANO-1,3A,4,9B-TETRAHYDRO(1)BENZOPYRANO(3,4-C)PYRROL-2(3H)-YL)ETHYL)PHENYL)ACETAMIDE; NEUROLEPTIC AGENT;

AVERSION; AVOIDANCE BEHAVIOR; CHAKRAGATI MOUSE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC TRANSMISSION; ENDOCRINE FUNCTION; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; FERTILITY; GENETIC MANIPULATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HEAD TWITCH; INSULIN RELEASE; LOCOMOTION; MATERNAL NUTRITION; MOUSE STRAIN; NEGATIVE SYNDROME; NERVOUS SYSTEM DEVELOPMENT; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMITTER RELEASE; NONHUMAN; PATERNAL AGE; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PREGNANCY COMPLICATION; PREPULSE INHIBITION; PRIMATE; PRIORITY JOURNAL; PROLACTIN RELEASE; RECOGNITION; REELER MOUSE MUTANT; REVIEW; RODENT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SEROTONINERGIC SYSTEM; SOCIAL DISCRIMINATION; SOCIAL RECOGNITION; STRAIN DIFFERENCE; TRANQUILIZING ACTIVITY; VERBAL MEMORY; VOCALIZATION; WEANING; WINTER; WORKING MEMORY; ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PYRAMIDAL NERVE CELL;

ACETANILIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOPYRANS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; HUMANS; MICE; MICE, NEUROLOGIC MUTANTS; PYRAMIDAL CELLS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 54449094499     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2008041     Document Type: Article

References (526)

1. Meltzer HY. Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 2004; 9: 15-24
2. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006; 31: 2033-46
3. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370
4. McClellan JM, Susser E, King M.-C. Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 194-9
5. Apud JA, Weinberger DR. Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs. NeuroRx 2006; 3: 106-16
6. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-47
7. Robertson GS, Hori SE, Powell KJ. Schizophrenia: an integrative approach to modelling a complex disorder. J Psychiatry Neurosci. 2006, 31: 157-67
8. O'Tuathaigh CMP, Babovic D, O'Meara G, et al. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 2007; 31: 60-78
9. Rapoport JL, Addington AM, Frangou S, et al. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10: 434-49
10. Maki P, Veijola J, Jones PB, et al. Predictors of schizophrenia: a review. Br Med Bull 2005; 73-74: 1-15
11. Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161: 889-95
12. Ozawa K, Hashimoto K, Kishimoto T, et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006; 59: 546-54
13. Pearce BD. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 2001; 6: 634-46
14. Di Forti M, Morrison PD, Butt A, et al. Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007; 20: 228-34
15. Henquet C, Murray R, Linszen D, et al. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005; 31: 608-12
16. Linszen D, van Amelsvoort M. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007, 20: 116-20
17. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002; 51: 775-87
18. Myin-Germeys I, Delespaul P, van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol Med 2005; 35: 733-41
19. Moore TH, Zammit S, Lingford-Hughes A. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28
20. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. Med Genet 2005; 42: 193-204
21. Crow TJ. How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry 2007; 164: 13-21
22. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320: 539-43
23. Chubb JE, Bradshaw NJ, Soares DC, et al. The DISC locus in psychiatric illness. Mol Psychiatry 2008; 13: 36-64
24. Hennah W, Thomson P, McQuillin A, et al. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 2008; Mar 4 doi:10.1038/mp.2008.22
25. Matsuzaki S, Tohyama M. Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). Neurochem Int 2007; 51: 165-72
26. Millar JK, Mackie S, Clapcote SJ, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 2007; 584: 401-5
27. Sawamura N, Sawa A. Disrupted-in-schizophrenia-1 (DISC1): a key susceptibility factor for major mental illnesses. Ann N Y Acad Sci 2006; 1086: 126-33
28. Fatemi SH, King DP, Reutiman TJ, et al. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 2008; 101: 36-49
29. Murdoch H, Mackie S, Collins DM, et al. Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 2007; 27: 9513-24
30. Numata S, Ueno SI, Iga JI, et al. Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. J Psychiatr Res 2008; doi:10.1016/j.jpsychires.2008.01.013
31. Andrieux A, Salin PA, Job D, et al. A role for microtubules in mental diseases? Pathol Biol 2004; 52: 89-92
32. Andrieux A, Salin P, Schweitzer A, et al. Microtubule stabilizer ameliorates synaptic function and behaviour in a mouse model for schizophrenia. Biol Psychiatry 2006; 60: 1224-30
33. Bosc C, Andrieux A, Job D. STOP proteins. Biochemistry 2003; 42: 12125-32
34. Fradley RL, O'Meara GF, Newman RJ, et al. Stop knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 2005; 163: 257-64
35. Powell KJ, Hori SE, Leslie R, et al. Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci 2007; 121: 826-35
36. Chen J, Lipska BK, Weinberger DR. Genetic mouse models to schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 2006; 59: 1180-8
37. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004; 8: 325-35
38. Gogos JA, Gerber DJ. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sci 2006; 27: 226-33
39. Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006; 19: 158-64
40. El-Ghundi M, O'Dowd BF, George SR. Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci 2007; 18: 37-66
41. Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 2007; 17: 171-81
42. Tanaka S. Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Neuroscience 2006; 139: 135-71
43. Lewis DA, Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 2007; 78: 109-31
44. Straub RE, Lipska BK, Egan MF, et al. Allelic variation in GAD1 (GAD-67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 2007; 12: 854-69
45. Harrisson PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68
46. Lang UE, Puls I, Müller DJ, et al. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007; 20: 687-702
47. Georgi A, Jamra RA, Klein K, et al. Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample. Psychiatr Genet 2007; 17: 308-10
48. Li D, He L. Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis. Genet Med 2007; 9: 4-8
49. Qin S, Zhao X, Pan Y, et al. An association study of the NMDA receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 2005; 13: 807-14
50. Martucci L, Wong AH, De Luca V, et al. N-demethyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 2006; 84: 214-21
51. Zhao X, Li H, Shi Y, et al. Significant association between the genetic variations in the 5' end of the NMDA receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 2006; 59: 747-53
52. Millan MJ. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 2002; 1: 191-213
53. Millan MJ. NMDA receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 2005; 179: 30-53
54. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for Damino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002; 99: 13675-80
55. Corvin A, McGhee KA, Murphy K, et al. Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 949-53
56. Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006; 60: 106-14
57. Hall J, Whalley HC, Moorhead TW, et al. Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia. Biol Psychiatry 2008; Apr 17, doi:10.1016/j.biopsych.2008.03.009
58. Shi J, Badner JA, Gershon ES, et al. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res 2008; 98: 89-97
59. Wood LS, Pickering EH, Dechairo BM, et al. Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol Psychiatry 2007; 61: 1195-9
60. Goldberg TE, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006; 31: 2022-32
61. Gerber DJ, Hall D, Miyakawa T, et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 2003; 100: 8993-8
62. Liu YL, Fann CS, Liu CM, et al. More evidence supports the association of PPP3CC with schizophrenia. Mol Psychiatry 2007; 12: 966-74
63. Miyakawa T, Leiter LM, Gerber DJ, et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA 2003; 100: 8987-92
64. Jaffrey SR, Snowman AM, Eliasson MJ, et al. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998; 20: 115-24
65. Xu B, Wratten N, Charych EI, et al. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PloS Med 2005; 2: e263 (999-1007)
66. Brunskill EW, Ehrman LA, Williams MT, et al. Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. Eur J Neurosci 2005; 22: 1265-76
67. Kamnasaran D, Muir WJ, Ferguson-Smith MA, et al. Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J Med Genet 2003; 40: 325-32
68. Pickard BS, Christoforou A, Thomson PA, et al. Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol Psychiatry 2008; doi: 10.1038/mp.2008.24
69. Benzel I, Bansal A, Browning BL, et al. Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct 2007; 3: 31-42
70. Kampmanns O, Anttila S, Illi A, et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004; 15: 2517-20
71. Mufano MR, Thiselton DL, Clark TG, et al. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11: 539-46
72. Silberberg G, Darvasi A, Pinkas-Kramarski R, et al. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 142-8
73. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 824-8
74. Li B, Woo RS, Mei L, et al. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007; 54: 583-97
75. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G protein signaling and beyond. Pharmacol Ther 2007; 116: 473-95
76. Bakker SC, Hoogendoorn ML, Hendriks J, et al. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 2007; 6: 113-9
77. Chowdari KV, Bamne M, Joel W, et al. Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia. Schizophr Bull 2008; 34:118-26
78. Buckholtz JW, Meyer-Lindenberg A, Honea RA, et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 2007; 27: 1584-93
79. Prasad KM, Chowdari KY, Nimgaonkar VL, et al. Genetic polymorphism of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol Psychiatry 2005; 10: 213-9
80. Li D, He L. Association study of the G-protein signalling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. Eur J Hum Genet 2006; 14: 1130-5
81. Jacquet H, Demily C, Hougit, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 2005; 10: 479-85
82. Liu H, Abecasis GR, Heath, SC, et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002; 99: 3717-22
83. Sanders AR, Duan J, Levison DF, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008; 165: 497-506
84. Renick SE, Kleven DT, Chan J, et al. The mammalian brain high-affinity L-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J Neurosci 1999; 19: 21-33
85. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007; 104: 16621-6
86. Hashimoto T, Hashimoto K, Miyatake R, et al. Association study between polymorphisms in glutathione-related genes and metamphetamine use disorder in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 2008; doi: 10.1002/ajmg.b.30703
87. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nature Genetics 2004; 36: 131-137
88. Kalkman HO. The role of phosphatidylinositide 3-kinase-protein-kinase B pathway in schizophrenia. Pharmacol Ther 2006; 110: 117-134
89. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71: 337-48
90. Straub RE, Mayhew MB, Vakkalanka RK, et al. Detection of dysbindin (DTNBP1) effects on clinical and cognitive phenotypes can be highly dependent on variation in COMT. Am J Med Genet B Neuropsychiatr Genet 2005; 138B: 135-6
91. Talbot K, Eiden WL, Tinsley CC, et al. Dysbindin-1 is reduced in intrinsic glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 113: 1353-63
92. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expresssion in normal brain and in schizophrenic prefrontal cortex. Arch Gen Psychiatry 2004; 61: 544-55
93. Numakawa T, Yagasaki Y, Ishimoto T, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004; 13: 2699-708
94. Kumamoto N, Matsuzaki S, Inoue K, et al. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributated to the downregulation of dysbindin. Biochem Biophys Res Commun 2006; 345: 904-9
95. 1 internalization. J Neurosci 2007; 27: 12390-5
96. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90
97. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007; 21: 283-301
98. Linden AM, Schoepp DD. Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discov Today: Ther Stategies 2006; 3: 507-17
99. Meaney MJ. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 2001; 24: 1161-92
100. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. J Psychopharmacol 2007; 21: 440-52
101. Kapur S, Agid O, Mizrahi R, et al. How antipsychotics work - from receptors to reality. NeuroRx 2006; 3: 10-21
102. 2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001; 25: 633-41
103. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 2001; 41: 237-60
104. De Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interactions and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005; 11: 3561-94
105. Enomoto T, Noda Y, Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 2007; 29: 291-301
106. Lindsley CW, Shipe WD, Wolkenberg SE, et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 2006; 6: 771-85
107. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-500
108. 2A receptor activation. J Pharmacol Exp Ther 2007; 320: 437-47
109. Rorick-Kehn LM, Johnson BG, Knitowski KM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 2007; 193: 121-36
110. 1A agonists. J Pharmacol Exp Ther 1995; 273: 101-12
111. 2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53: 439-52
112. Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-7
113. 1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61
114. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159-72
115. Werkman TR, Glennon JC, Wadman WJ, et al. Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. CNS Neurol Disord Drug Targets 2006, 5: 3-23
116. Geyer MA, Markou A. Animal models of psychiatric disorders. Psychopharmacology 1995; 68: 787-92
117. Geyer MA, Ellenbroek B. Animal behaviour models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1071-9
118. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004; 29: 282-6
119. Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001; 26: 395-410
120. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64: 2291-314
121. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1-93
122. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14: 152-64
123. Marino MJ, Knutsen LJS, Williams M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J Med Chem 2008; 51: 1077-107
124. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 1998; 286: 1356-73
125. Millan MJ, Brocco M, Rivet JM, et al. S18327 (1-{2-[4-(6-fluoro 1,2-benzisoxazol-3-yl) piperid-1-yl] ethyl} 3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at 1- and 2-adrenergic receptors: II. functional profile, and a multiparametric comparison to haloperidol, clozapine and 11 other antipsychotic agents. J Pharmacol Exp Ther 2000; 292: 54-66
126. Millan MJ. The discovery and development of pharmacotherapy for psychiatric disorders: a critical survey of animal and translational models, and perspectives for their improvement Animal and translational models for CNS drug discovery. Vol 1. Psychiatric disorders. In: RA McArthur and F Borsini editors. Elsevier NY 2008 (in press)
127. Moore NA. Behavioural pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 1999; 174: 5-11
128. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007; 15: 245-58
129. McCue RE, Waheed R Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 433-40
130. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 1999; 163: 600-10
131. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104
132. Serretti A, De Roncji D, Lorenzi C, et al. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004; 11: 343-58
133. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007; 164: 415-27
134. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-72
135. Stanford AD, Sharif Z, Corcoran C, et al. rTMS strategies for the study and treatment of schizophrenia: a review. Int J Neuropsychopharmacol 2008; 11: 563-76
136. Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004; 61: 866-76
137. 3- receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1048-62
138. 3-receptors: II. Functional and behavioural profile compared with GR18,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1063-73
139. 3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005; 10: 917-25
140. Joyce JN. Dopamine D3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90: 231-59
141. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43
142. 3 receptor preferring agonist in vivo Synapse 2006; 60: 485-95
143. 4 dopamine receptor mRNA is reduced in CD4+ T cells. J Neuroimmunol 2006; 173: 180-7
144. 3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci USA 2001; 16: 625-8
145. 3 receptors in rat central nervous system and blood cells. Neuropharmacology 2006; 51: 923-32
146. 3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. J Pharmacol Exp Ther 2000; 294: 1166-74
147. Bespalov A, Jongen-Rêlo AL, van Gaalen M, et al. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 2007; 320: 944-50
148. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 2003; 45: 174-81
149. 3 dopamine receptors. Eur J Neurosci 2004; 20: 3189-94
150. 3 receptor antagonism SB-277011-A on regional c-Fos like expression in rat forebrain. Brain Res 2007; 1149: 50-7
151. 3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 2006; 31: 2368-75
152. 3 receptors attenuated cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007; 10: 167-81
153. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 2005; 49: 77-105
154. 3 receptor agonist BP-897 attenuate metamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 2008; 196: 533-42
155. 3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2005; 15: 1016-24
156. 3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anticholinesterases. J Neurosci Methods 2006; 157: 25-31
157. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 2005; 179: 567-75
158. 1 receptor antagonist. Eur Neuropsychopharmacol 2006; 16: S256
159. 2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007; 100: 954-67
160. Loiseau F, Millan MJ. Frontocortical blockade of dopamine D3, but not D2, receptors enhances social recognition in rats: a comparison to D1 receptor activation. Eur Neuropsychopharmacoly. In press
161. 3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder. Human Psychopharmacol 2008; 23: 267-74
162. Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23: 61-7
163. 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 2004; 174: 341-57
164. 3, dopamine receptors. Mov Disord 2006; 21: 2090-5
165. 3 receptor antagonists, SB277011-A and S33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007; 872: 171-4
166. 2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions of G-protein-coupled receptors. J Pharmacol Exp Ther 2008; 324: 587-99
167. 2 receptor antagonist and potential antipsychotic agent: II. A neurochemical, electrophysiological and behavioral characterization in vivo J Pharmacol Exp Ther 2008; 324: 600-11
168. 2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008; 324: 1212-26
169. 3 receptors for the activation of extracellular signal-regulated kinase. J Biol Chem 2004; 279: 28304-14
170. 3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol-3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacology 1999; 56: 1025-30
171. 1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exper Ther 1998; 286: 1341-55
172. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signalling. J Recept Signal Transduct Res 2004; 24: 165-205
173. 35 S]thio)-triphosphate binding and antibody study. Mol Pharmacol 1999; 55: 564-74
174. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 2003; 462: 33-40
175. Svensson TH. α-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1145-58
176. 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 2007; 10: 191-202
177. 2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 2001; 68: 363-70
178. 7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 2008; 19: 153-9
179. 2A sites for induction of locomotion by PCP in the rat. Eur J Neurosci 1999; 11: 4419-32
180. Hagan JJ, Jones DNC. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 2005; 31: 830-53
181. Kroeze WK, Hufeison SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-26
182. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 2004; 10: 2463-75
183. 4 receptors: an in vitro and in vivo comparison to L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b] pyridine) and raclopride. J Pharmacol Exper Ther 1998; 287: 167-86
184. Li M, Fletcher PJ, Kapur S. Time course of the antipsychotic effects and the underlying behavioural mechanisms. Neuropsychopharmacology 2007; 32: 263-72
185. Siuciak JA, Chapin DS, McCarthy SA, et al. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 2007; 192: 415-24
186. Olsen CK, Kreilgaard M, Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav 2006; 84: 259-65
187. Takamori K, Hirota S, Chaki S, et al. Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci 2003; 73: 1721-8
188. 2C receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev 2006; 12: 167-77
189. 2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007; 52: 279-90
190. Featherstone RE, Rizos Z, Kapur S, et al. A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res 2008; 189: 170-9
191. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2006; 20: 15-27
192. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000; 294: 1154-65
193. 2A receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 2001; 297: 357-63
194. Woolley ML, Pemberton DJ, Bate S, et al. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008; 196: 431-40
195. 3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur J Neurosci 2005; 21: 3415-26
196. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
197. Krystal JH, Perry EB, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62: 985-94
198. Mouri A, Noda Y, Enomoto T, et al. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochemistry Int 2007; 51: 173-84
199. Millan MJ, Gobert A, Bervoets K, et al. Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents. J Pharmacol Exp Ther 2000: 292: 672-83
200. Chartoff EH, Heusner CL, Palmiter RD. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005; 30: 1324-33
201. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at sertonin, 5-HT(1) and 5-HT(2) receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-22
202. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804
203. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 2004; 29: 1637-47
204. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 2004; 174: 175-85
205. Bramon E, Rabe-Hesketh S, Sham P. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004; 70: 315-29
206. Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006; 27: 391-8
207. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007; 11: 1189-206
208. Weiss IC, Feldon J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology 2001; 156: 305-26
209. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001; 156: 234-58
210. Geyer MA, Krebs-Thomson K, Braff DL, et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117-54
211. Linn GS, Negi SS, Gerum SV, et al. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology 2003; 169: 234-9
212. Swerdlow NR, Light GA, Cadenhead KS, et al. Startle gating deficits in a large cohort of patients with schizophrenia. Arch Gen Psychiatry 2006; 63: 1325-35
213. Swerdlow NR, Sprock J, Light GA, et al. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the consortium on the genetics of schizophrenia. Schizophr Res 2007; 92: 237-51
214. Meincke U, Morth D, Voss T, et al. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis - a longitudinal study. Eur Arch Psychiatry Clin Neurosci 2004; 254: 415-21
215. 3 antagonists on PPI deficits induced by PD128907 and apomorphine. Behav Brain Res 2007; 182: 1-11
216. 3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006; 31: 1382-92
217. Cilia J, Hatcher P, Reavill C, et al. (±) ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 2007; 21: 302-11
218. Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents - relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev 2008; document doi:10.1016/j.neubiorev.2008.03.003
219. 7 nicotinic receptor agonist. Psychopharmacology 2005; 182: 214-9
220. Cilia J, Hatcher PD, Reavill C, et al. Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats: an update. Psychopharmacology 2005; 180: 57-62
221. 3 agonist ropinirole in healthy males. Psychopharmacology 2007; 194: 289-95
222. 3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex. Biol Psychiatry 2008; doi:10.1016/j.biopsych.2008.01.020
223. 3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology 2006; 31: 1335-44
224. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56: 301-7
225. Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 2003; 660: 285-98
226. Glahn DC, Ragland JD, Abramoff A, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping 2005; 25: 60-9
227. Bacciottini L, Passani MB, Mannaioni PF, et al. Interactions between histaminergic and cholinergic system in learning and memory. Behav Brain Res 2001; 124: 183-94
228. Ito C. The role of the central histaminergic system on schizophrenia. Drug News Perspect 2004; 17: 383-7
229. Sarter M, Nelson CL, Bruno JP. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 2005; 31: 117-38
230. 1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 2007; 22: 1-17
231. 1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000; 20: 1208-15
232. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004; 174: 3-16
233. Lapiz MDS, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006; 137: 1039-49
234. 2A receptors minimally contribute to clozapine induced acetylcholine release in rat medial prefrontal cortex. Brain Res 2002; 939: 34-42
235. Johnson DE, Nedza FM, Spracklin DK, et al. The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol 2005; 506: 209-19
236. 1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol 2007; 559: 155-66
237. 7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007; 74: 1192-201
238. Beer JS, Ochsner KN. Social cognition: a multi-level analysis. Brain Res 2006; 1079: 98-105
239. Lee KH, Brown WH, Egleston PN, et al. A functional magnetic resonance imaging study of social recognition in schizophrenia during an acute episode and after recovery. Am J Psychiatry 2006; 163: 1926-33
240. Boess FG, De Vry J, Erb C, et al. The novel ?7 nicotinic acetylcholine receptor agonist N-[(3R]-1-azabicyclo[2.2.2]oct-3-yl]-7-[2- (methoxy)phenyl]-1-benzofuran-2-carboxa mide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007; 321: 716-25
241. 6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology 2008; 196: 93-104
242. 4 partial agonist properties: (III) activity inmodels of cognition and negative symptoms. Br J Pharmacol 2007; 151: 266-77
243. Depoortère R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-85
244. 1A receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 2005; 181: 134-44
245. Barker GR, Bird F, Alexander V, et al. Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 2007; 27: 2948-57
246. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007; 31: 673-704
247. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a subchronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007; 184: 31-8
248. 2 receptor antagonist, S33138, reverses delay-dependent and isolation rearing-induced deficits in novel object recognition in rats. J Psychopharmacol 2008; in press. [Il s'agit de l'abstract d'une présentation qui sera faite au British Association Psychopharmacology meeting à Harrogate (UK) du 20 au 23 Juillet 2008]
249. Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002; 163: 362-80
250. Chudasama Y, Robbins TW. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology 2004; 174: 86-98
251. 2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 2007; 32: 273-83
252. DayM, Pan JB, Buckley MJ, et al. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 2007; 73: 1123-34
253. Mirza NR, Stolerman IP. The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology 2000; 148: 243-50
254. Rezvani AH, Caldwell DP, Levin ED. Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 190-7
255. Passetti F, Levita L, Robbins TW. Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav Brain Res 2003; 138: 59-69
256. Decamp E, Schneider JS. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 2004; 20: 1371-8
257. Decamp E, Schneider JS. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. Eur J Neurosci 2006; 24: 2098-101
258. Buccafusco JJ, Weiser T, Winter K, et al. The effects of IDRA 21, a positive modulator for the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology 2004; 46: 10-22
259. Buccafusco JJ, Jackson WJ, Terry AV, et al. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 1995; 120: 256-66
260. Hou Y, Wu CF, Yang JY, et al. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1486-95
261. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007; 572: 161-70
262. 2 receptors in rats. Eur J Pharmacol 2003; 474: 227-32
263. Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neurosci 2002; 3: 563-73
264. Kosson DS, Budhani S, Nakic M, et al. The role of the amygdala and rostral anterior cingulate in encoding expected outcomes during learning. Neuroimage 2006; 29: 1161-72
265. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244
266. Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45: 460-68
267. Huppert JD, Smith TE. Anxiety and schizophrenia: the interaction of subtypes of anxiety and psychotic symptoms. CNS Spectrums 2005; 10: 721-31
268. Millan MJ, Brocco M, Gobert A, et al. S16924 [(R)-2-[1-[2-(2,3- dihydrobenzol[ 1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluorophenyl)- ethanone], a novel, potential antipsychotic with marked serotonin1a agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 1999; 288: 1002-114
269. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005; 60: 441-60
270. Wesolowska A, Nikiforuk A, Stachowicz K. Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur J Pharmacol 2006; 553: 185-90
271. 3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav 1997; 63: 137-41
272. Millan MJ, Brocco M. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 2003; 463: 67-96
273. 2A precursor protein. Depress Anxiety 2005; 22: 84-93
274. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22: 724-63
275. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology 1996; 15: 53-61
276. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-6
277. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatr 2001; 62: 4-10
278. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatr 2001; 62: 23-29
279. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000; 101: 416-32
280. 3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo Cell Metab 2006; 3: 449-61
281. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets. Diabetes 2005; 54: 1552-8
282. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro Eur Neuropsychopharmacol 2004; 14: 115-9
283. 3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005; 27: 289-304
284. Matsui-Sakata A, Ohtani H, Sawada T, et al. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotic-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20: 368-378
285. 2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280: 36824-32
286. Hajduch E, Rencurel F, Balendran A, et al. Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 1999; 274: 13563-8
287. Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005; 10: 1089-96
288. Ardizzone TD, Bradley RJ, Freeman AM, et al. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001; 923(1-2): 82-90
289. Cooper GD, Harrold JA, Halford JC, et al. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 428-36
290. Fell MJ, Anjum N, Dickinson K, et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology 2007; 194: 221-31
291. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003; 75: 255-60
292. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverses metabolic effects. Neuropsychopharmacology 2007; 32: 289-97
293. Murashita M, Kusumi I, Hosoda H, et al. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007; 32: 777-84
294. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 2004; 61: 1822-8
295. Patterson JV, Hetrick WP, Boutros NN, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008; 158(2): 226-47
296. 3 receptor antagonist. J Pharmacol Exp Ther 2005; 313: 176-90
297. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; doi: 10.1038/sj.npp.1301624
298. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a metaanalysis. Schizophr Res 2005; 76: 1-23
299. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 2005; 62: 127-36
300. Umbricht D, Vyssotki D, Latanov A, et al. Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice? Clin Neurophysiol 2005; 116: 353-363
301. Moser PC, Hitchcock JM, Lister S, et al. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 2000; 33: 275-307
302. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003; 169: 257-97
303. Feldon J, Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 1992; 26: 345-66
304. Chagas-Martinich L, Carey RJ, Carrera MP. 7-OH-DPAT effects on latent inhibition: low dose facilitation but high dose blockade: implications for dopamine receptor involvement in attentional processes. Pharmacol Biochem Behav 2007; 86: 441-8
305. Egerton A, Reid L, McGregor S, et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 2008; 198: 37-49
306. Rodefer JS, Murphy ER, Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005; 21: 1070-6
307. Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 2005; 57: 433-6
308. Goetghebeur P, Dias R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat - a back translational study. Psychopharmacology 2008; doi: 10.1007/s00213-008-1132-9
309. McLean SL, Beck JP, WoolleyML, et al. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 2008; 189: 152-8
310. Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 2003; 17: 57-65
311. Idris NF, Repeto P, Neill JC, et al. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 2005; 179: 336-48
312. Lim EP, Verma V, Nagarajah R, et al. Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task. Psychopharmacology 2007; 191: 297-310
313. Didriksen M, Skarsfelt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris water maze by sertindole and other antipsychotics. Psychopharmacology 2007; 193: 225-33
314. Montgomery SA, van Zwieten-Boot B. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Eur Neuropsychopharmacol 2007; 17: 70-7
315. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 1995; 6: 55-65
316. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996; 7: 3-23
317. Snigdha S, Neill JC. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - a preliminary investigation. Behav Brain Res 2008; 187: 489-94
318. 3 receptor antagonist: neurochemical and electrophysiological studies in vivo Am Soc Neurosci Abstr 2005; 31: 913-9
319. Poleszak E, Wlaz P, Wrobel A, et al. Activation of the NMDA-glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep 2007; 59: 595-600
320. Noda Y, Yamada K, Furukawa H, et al. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995; 116: 2531-7
321. Noda Y, Kamei H, Mamiya T, et al. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000; 23: 375-87
322. Nagai T, Noda Y, Une T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport 2003; 14: 269-72
323. 1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 1999; 289: 427-36
324. Goudie AJ, Smith JA. Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 1999; 64: 193-201
325. Goudie AJ, Smith JA, Millan MJ. Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 2004; 171: 212-22
326. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23: 223-39
327. Bakshi VP, Geyer MA. Ontogeny of isolation rearing-induced deficits in sensorimotor gating in rats. Physiol Behav 1999; 67: 385-92
328. Diergaarde L, Gerrits MA, Stuy A, et al. Neonatal amygdala lesions and juvenile isolation in the rat: differential effects on locomotor and social behavior later in life. Behav Neurosci 118; 2004: 298-305
329. Ellenbroek BA, van den Kroonenberg PT, Cools AR. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophr Res 1998; 30: 251-60
330. Ibi D, Takuma K, Koike H, et al. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J Neurochem 2008; 105(3): 921-32
331. Pietropaolo S, Singer P, Feldon J, et al. The postweaning social isolation in C57BL/6 mice: preferential vulnerability in the male sex. Psychopharmacology 2008; 197: 613-28
332. Weiss IC, Pryce CR, Jongen-Relo AL, et al. Effect of social isolation on stress-related behavioural and neuroendocrine state in the rat. Behav Brain Res 2004; 152: 279-95
333. 3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology 2005; 180: 705-15
334. Shah YB, Marsden CA. The application of functional magnetic resonance imaging to neuropharmacology. Curr Opin Pharmacol 2004; 4: 517-21
335. McGuire P, Howes OD, Stone J, et al. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci 2008; 29(2):
336. Weinberger DR. Neurodevelopmental perspectives on schizophrenia. Psychopharmacology 1995; 98: 1171-81
337. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Res Rev 2004; 45: 1-17
338. Schmidt-Kastner R, van Os J, Steinbursch WM, et al. Gene regulation by hypoxia and the neurodevelopemental origins of schizophrenia. Schizophr Res 2006; 84: 253-71
339. Tejkalova H, Kaiser M, Klaschka J, et al. Does neonatal brain ischemia induce schizophrenia-like behavior in young adult rats? Physiol Res 2007; 56: 815-23
340. Meyer U, Nyffeler M, Yee BK, et al. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008; 22: 469-86
341. Meyer U, Nyffeler M, Schwendener S, et al. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008; 33: 441-56
342. A receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience 2006; 143: 51-62
343. Zuckerman L, Rehavi M, Nachman R, et al. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003; 28: 1778-89
344. Fatemi SH, Pearce DA, Brooks AI, et al. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 2005; 57: 91-9
345. Fatemi SH, Reutiman TJ, Folsom TD, et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 2008; 99: 56-70
346. Shi L, Fatemi SH, Sidwell RW, et al. Maternal influence infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003; 23: 297-302
347. Nawa H, Takei N. Recent progess in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006; 56: 2-13
348. TohmiM, Tsuda N, Watanabe Y, et al. Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci Res 2004; 50: 67-75
349. Becker A, Grecksch G. Social memory is impaired in neonatally ibotenic acid lesioned rats. Behav Brain Res 2000; 109: 137-40
350. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9: 67-75
351. Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus results in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997; 132: 303-10
352. Kamath A, Al-Khairi I, Bhardwaj S, et al. Enhanced alpha1 adrenergic sensitivity in sensorimotor gating deficits in neonatal ventral hippocampus-lesioned rats. Int J Neuropsychopharmacol 2008; 6: 1-12
353. Tseng KY, Amin F, Lewis BL, et al. Altered prefrontal cortical metabolic response to mesocortical activation in adult animals with a neonatal ventral hippocampal lesion. Biol Psychiatry 2006; 60: 585-90
354. Tseng KY, Lewis BL, Lipska BK, et al. Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry 2007; 62: 730-8
355. Alguicer G, Morales-Medina JC, Quirion R, et al. Postweaning social isolation enhances morphological changes in the neonatal ventral hippocampal lesion rat model of psychosis. J Chem Neuroanat 2008; 35: 179-87
356. Swerdlow NR, Lipska BK, Weinberger DR, et al. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology 1995; 122: 27-34
357. Levin ED, Christopher NC. Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 223-9
358. Rueter LE, Ballard ME, Gallagher KB, et al. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology 2004; 176: 312-9
359. Daenen EW, Wolterink G, Gerrits MA, et al. The effects of neonatal lesions in the amygdala or ventral hippocampus on social behaviour later in life. Behav Brain Res 136; 2002: 571-82
360. Daenen EW, Wolterink G, Van Ree JM. Hyperresponsiveness to phencyclidine in animals lesioned in the amygdala on day 7 of life. Implications of an animal model of schizophrenia. Eur Neuropsychopharmacol 2003; 13: 273-9
361. Shoemaker JM, Pitcher L, Noh HR, et al. Quetiapine produces a prolonged reversal of the sensorimotor gating-disruptive effects of basolateral amygdala lesions in rats. Behav Neurosci 2003; 117: 136-43
362. Schiller D, Zuckerman L, Weiner I. Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol. J Psychiatr Res 2006; 40: 167-77
363. Flagstad P, Mork A, Glenthoj BY, et al. Disruption of neurogenesis on gestational day 17 in the rat causes behavioural changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 2004; 29: 2052-64
364. Gourevitch R, Rocher C, Le Pen G, et al. Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol 2004; 15: 287-92
365. Moore H, Jentsch JD, Ghajarnia M, et al. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications of the neuropathology of schizophrenia. Biol Psychiatry 2006; 60: 253-64
366. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645-60
367. Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology 2005; 30: 1426-35
368. Le Pen G, Gourevitch R, Hazane F. Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. Neuroscience 2006; 143: 395-405
369. Léna I, Chessel A, Le Pen G, et al. Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17. Psychopharmacology 2007; 192: 373-83
370. Jongen-Rêlo AL, Leng A, Lüber M. The prenatal methylazoxymethanol acetate treatment: a neurodevelopmental animal model for schizophrenia? Behav Brain Res 2004; 149: 159-81
371. Featherstone RE, Rizos Z, Nobreja JN, et al. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 2007; 32: 483-92
372. Penschuck S, Flagstad P, Didriksen M, et al. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 2006; 23: 279-84
373. Wang C, McInnis J, Ross-Sanchez S, et al. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001; 107: 535-50
374. Rasmussen BA, O'Neil J, Manaye KF, et al. Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats. Psychopharmacology 2007; 190: 43-49
375. Wedzony K, Fijal K, Mackiwiak M, et al. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behaviour: a search for a new developmental model of schizophrenia. Neuroscience 2008; 153: 1370-9
376. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004; 29: 1080-90
377. Broberg BV, Dias R, Glenthoj BY, et al. Evaluation of a neurodevelopmental model of schizophrenia-early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 2008; 190: 160-3
378. Harich S, Gross G, Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology 2007; 192: 511-9
379. Kawabe K, Iwasaki T, Ichitani Y. Repeated treatment with N-methyl-D-aspartate antagonists in neonatal, but not adult, rats causes long-term deficits of radial-arm maze learning. Brain Res 2007; 1169: 77-86
380. Latysheva NV, Rayevsky KS. Chronic neonatal N-methyl-D-aspartate receptor blockade induces learning deficits and transient hypoactivity in young rats. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 787-94
381. Harris LW, Sharp T, Gartlon J, et al. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 2003; 18: 1706-10
382. 7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007; 32: 17-34
383. Brooks WJ, Weeks AC, Leboutillier JC. Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism. Physiol Behav 1997; 62: 955-62
384. Wang CZ, Johnson KM. The role of caspase-3-activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 2007; 32: 1178-94
385. Abekawa T, Ito K, Nakagawa S, et al. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology 2007; 192: 303-16
386. Dringen R, Guterer JM, Hirrlinger J. Glutathione metabolism in brain. Metabolic interaction between astrocytes and neurons in the defence against reactive oxygen species. Eur J Biochem 2000; 267: 4912-6
387. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12: 3721-8
388. Steullet P, Neijt HC, Cuénod M, et al. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006; 137: 807-19
389. Matsuzawa D, Obata T, Shirayama Y, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PloS ONE 2008; 3: e1944
390. Castagné V, Cuénod M, Do KQ. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 2004; 123: 821-34
391. Jacobsen JP, Rodriguiz RM, Mørk A, et al. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia? Neuroscience 2005; 132: 1055-72
392. Cabungcal JH, Nicolas D, Kraftsik R, et al. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 2006; 22: 624-37
393. 3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience 2006; 143: 141-53
394. Shilling PD, Saint Marie RL, Shoemaker JM, et al. Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways. Biol Psychiatry 2008; 63: 748-58
395. Schwabe K, Freudenberg F, Koch M. Selective breeding of reduced sensorimotor gating in Wistar rats. Behav Gen 2007; 37: 706-12
396. Ellenbroek BA, Geyer MA, Cools AR. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J Neurosci 1995; 15: 7604-11
397. Ellenbroek BA, Cools AR. Apomorphine susceptibility and animal models for psychopathology: genes and environment. Behav Genet 2002; 32: 349-61
398. Wolf R, Paelchen K, Matzke K, et al. Acute or subchronic clozapine treatment does not ameliorate prepulse inhibition (PPI) deficits in CPB-K mice with low levels of hippocampal NMDA receptor density. Psychopharmacology 2007; 194: 93-102
399. Spielewoy C, Markou A. Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients. Behav Genet 2004; 34: 343-54
400. B receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. Psychopharmacology 2007; 194: 361-9
401. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000; 11: 223-33
402. Dawe GS, Ratty AK. The chakragati mouse: a mouse model for rapid in vivo screeening of antipsychotic drug candidates. Biotechnol J 2007; 2: 1344-52
403. Torres G, Hallas BH, Gross KW, et al. Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia. Brain Res Bull 2008; 75: 556-61
404. Verma V, Tan CH, Ong WY, et al. The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition. Neurosci Res 2008; 60: 281-8
405. D'Arcangelo G. The reeler mouse: anatomy of a mutant. Intern Rev Neurobiol 2005; 71: 383-417
406. Costa E, Dong E, Grayson DR, et al. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2007; 2: 29-36
407. Qiu S, Zhao LF, Korwek KM, et al. Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J Neurosci 2006; 26: 12943-55
408. Tueting P, Doueiri M-S, Guidotti A, et al. Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev 2006; 30: 1065-77
409. Carboni G, Tueting P, Tremolizzo L, et al. Enhanced dizocilpine efficacy in heterozygotous reeler mice relates to GABA turnover downregulation. Neuropharmacology 2004; 46: 1070-81
410. Salinger WL, Ladrow P, Wheeler C. Behavioral phenotype of the reeler mutant mouse: effects of Reln gene dosage and social isolation. Behav Neurosci 2003; 117: 1257-75
411. 67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci USA 2005; 102: 12578-83
412. Kundakovic M, Chen Y, Costa E, et al. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 2007; 71: 644-53
413. Hashimoto A, Nishikawa T, Konno R, et al. Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase. Neurosci Lett 1993; 152:33-6
414. Almond SL, Fradley RL, Armstrong EJ, et al. Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 2006; 32: 324-34
415. Maekawa M, Watanabe M, Yamaguchi S, et al. Spatial learning and long-term potentiation of mutant mice lacking D-amino-acid oxidase. Neurosci Res 2005; 53: 34-8
416. Hashimoto A, Yoshikawa M, Niwa A, et al. Mice lacking D-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. Brain Res 2005; 1033: 210-5
417. Hashimoto A, Konno R, Yano H, et al. Mice lacking D-amino acid oxidase activity exhibit marked reduction of methamphetamine-induced stereotypy. Eur J Pharmacol 2008; 586: 221-5
418. Hashimoto A, Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 1997; 52: 325-53
419. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41-51
420. Madeira C, Freitas ME, Vargas-Lopes C, et al. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008; 101: 76-83
421. Gogos JA, Santha M, Takacs Z, et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 1999; 21: 434-9
422. Paterlini M, Zakharenko SS, Lai WS, et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 2005; 8: 1586-94
423. Zinkstok J, Schmitz N, van Amelsvoort T, et al. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. Genes Brain Behav 2008; 7: 61-9
424. Arguello PA, Gogos JA. Schizophrenia: modeling a complex psychiatric disorder. Drug Discovery Today: Disease Models 2006; 3: 319-25
425. Nicodemus KK, Kolachana BS, Vakkalanka R, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G75, GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet 2007; 120: 889-906
426. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006; 7: 583-90
427. Nicodemus KK, Marenco S, Batten AJ, et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry 2008; doi:10.1038/sj.mp.4002153
428. Camargo LM, Collura V, Rain JC, et al. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2007; 12: 74-86
429. Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 2006; 86: 1-14
430. Callicott JH, Staub RE, Pezawas L, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 2005; 102: 8627-32
431. Cannon TD, Hennah W, van Erp TG, et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry 2005; 62: 1205-13
432. Roberts RC. Disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr Bull 2007; 33: 11-5
433. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 2007; 104: 14501-6
434. Pletnikov MV, Ayhan Y, Nikolskaia O, et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnomalities reminiscent of schizophrenia. Mol Psychiatry 2008; 13: 173-86
435. Li W, Zhou Y, Jentsch JD, et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci USA 2007; 104: 18280-5
436. Koike H, Arguello PA, Kvajo M, et al. DISC1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA 2006; 103: 3693-7
437. Clapcote SJ, Lipina TV, Millar JK. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007; 54: 387-402
438. Siuciak JA, McCarthy SA, Chapin DS. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 2008; 197: 115-26
439. Kanes SJ, Tokarczyk J, Siegel SJ, et al. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-46
440. Siuciak JA, McCarthy SA, Chapin DS, et al. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/B16N congenic background. Neuropharmacology 2008; 54: 417-27
441. Menniti FS, Chappie TA, Humphrey JM, et al. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007; 8: 54-9
442. Sano H, Nagai Y, Miyakawa T, et al. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 2008; 105: 546-56
443. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9: 1415-23
444. Brun P, Bégou M, Andrieux A, et al. Dopaminergic transmission in STOP null mice. J Neurochem 2005; 94: 63-73
445. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, et al. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004; 3: 515-33
446. Eastwood SL, Lyon L, George L, et al. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol 2007; 21: 635-44
447. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol-o-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family based studies. Am J Psychiatry 2003; 160: 469-76
448. Fan JB, Zhang CS, Gu NF, et al. Catechol-o-methyltransferase gene Val/Met functional polymorphism and risk for schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005; 57: 139-44
449. Mufano MR, L Bowes, Clark TG, et al. Lack of association of the COMT (Val158/108Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005; 10: 765-70
450. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007; 90: 86-96
451. Tunbridge E, Burnet PW, Sodhi MS, et al. Catechol-o- methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 2004; 51: 112-8
452. Yavich L, Forsberg MM, Karayiorgou M, et al. Site-specific role of catechol-O-methyltransferase in dopmaine overflow withih prefrontal cortex and dorsal striatum. J Neurosci 2007; 19: 10196-209
453. Babovic D, O'Tuathaigh CM, O'Sullivan GJ, et al. Exploratory and hatuation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res 2007; 183: 236-9
454. Gogos JA, Morgan M, Luine V, et al. Cathecol-O-methyltransferase- deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991-6
455. Huotari M, Garcia-Horsman JA, Karayiorgou M, et al. d-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology 2004; 172: 1-10
456. Dracheva S, Byne W, Chin B, et al. Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res 2008; 1214: 23-34
457. Duncan GE, Moy SS, Lieberman JA, et al. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 2006; 184: 190-200
458. Duncan GE, Moy SS, Lieberman JA, et al. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav 2006; 85: 481-91
459. Duncan GE, Moy SS, Perez A, et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 2004; 153: 507-19
460. Mohn AR, Gainetdinov RR, Caron MG, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-36
461. Bickel S, Lipp HP, Umbricht D. Impaired attentional modulation of auditory evoked potentials in N-methyl-D-aspartate NR1 hypomorphic mice. Genes Brain Behav 2007; 6: 558-68
462. Miyamoto S, Snouwaert JN, Koller BH, et al. Amphetamine-induced fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology 2004; 29: 2180-8
463. Ballard TM, Pauly-Evers M, Higgins GA, et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 2002; 22: 6713-23
464. Kew JNC, Koester A, Moreau JL, et al. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Neurosci 2000; 20: 4037-49
465. Spooren W, Mombereau C, Maco M, et al. Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhinition. Psychopharmacology 2004; 175: 99-105
466. Cheli V, Adrover M, Blanco C, et al. Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning. J Neurochem 2006; 97: 68-73
467. Rujescu D, Bender A, Keck M, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 2006; 59: 721-9
468. Kozlovsky N, Scarr E, Dean B, et al. Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. Schizophr Res 2006; 83: 173-7
469. Lee JI, Ahnn J. Calcineurin in animal behavior. Mol Cell 2004; 17: 390-6
470. Zeng H, Chattarji S, Barborosie, et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001; 107: 617-29
471. Erbel-Sieler C, Dudley C, Zhou Y, et al. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc Natl Acad Sci USA 2004; 101: 13648-53
472. Pieper AA, Wu X, Han TW, et al. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc Natl Acad Sci USA. 2005; 102: 14052-57
473. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60: 132-40
474. Corfas G, Roy C, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/ cellular basis of schizophrenia. Nat Neurosci 2004; 7: 575-80
475. Kanakry CG, Li Z, Nakai Y, et al. Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PloS one 2007; 2: e1369
476. Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr Bull 2008; 34: 72-92
477. McIntosh AM, Moorhead TW, Job D, et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry 2007; in press
478. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-92
479. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, et al. Neuregulin 1 and schizophrenia. Annals Med 2004; 36: 62-71
480. Chong VZ, Thompson M, Beltaifa S, et al. Elevated neuregulin-1 and ErB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008; 100: 270-80
481. Boucher AA, Arnold JC, Duffy L, et al. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9- tetrahydrocannabinol. Psychopharmacology 2007; 192: 325-36
482. 2A receptors and serotonin transporter in the CNS of neuregulin1 hypomorphic/mutant mice. Schizophr Res 2008; 99: 341-9
483. Karl T, Duffy L, Scimone A, et al. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 2007; 6: 677-87
484. O'Tuathaigh CMP, Babovic D, O'Sullivan GJ, et al. Phenotypic characterization of spatial cognition and social behavior in mice with "knockout" of the schizophrenia risk gene neuregulin 1. Neuroscience 2007; 147: 18-27
485. O'Tuathaigh CMP, O'Connor A-M, O'Sullivan GJ, et al. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous "knockout" of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 462-6
486. Rimer M, Barrett DW, Maldonado MA, et al. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 2005; 16: 271-5
487. Hu X, Hicks CW, He W, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006; 9: 1520-5
488. Savonenko AV, Melnikova T, Laird FM, et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 2008; 105: 5585-90
489. Gerlai R, Pisacane P, Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 2000; 109: 219-27
490. Golub MS, Germann SL, Lloyd KC. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res 2004, 153: 159-70
491. Thuret S, Alavian KN, Gassmann M, et al. The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta. J Neurochem 2004; 91: 1302-11
492. Roy K, Murtie JC, El-Khodor B, et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA 2007; 104: 8131-6
493. Haroutunian V, Davis KL. Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol 2007; 10: 499-502
494. Bowden NA, Scott RJ, Tooney PA. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 2007; 89: 165-8
495. Erdely HA, Tamminga CA, Roberts RC, et al. Regional alterations in RGS4 protein in schizophrenia. Synapse 2006; 59: 472-9
496. Puri V, McQuillin A, Choudhury K, et al. Fine mapping by genetic association implicates the chromosome lq23.3 gebe UHMK1, encoding a serine/ threonine protein kinase, as a novel schizophrenia susceptibility gene. Biol Psychiatry 2007; 61: 873-9
497. Grillet N, Pattyn A, Contet C, et al. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 2005; 25: 4221-8
498. 3 dopamine receptors in vivo. J Neurosci 2007; 27: 881-5
499. Lai W-S, Xu B, Westphal KGC, et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 2006; 103: 16906-11
500. Thiselton DL, Vladimirov VI, Kuo P-H, et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 2008; 63: 449-57
501. 1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-8
502. 1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 15312-7
503. 1 muscarinic acetylcholine receptor. J Neurosci 2001; 21: 5239-50
504. Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosone 15 locus. Proc Natl Acad Sci USA 1997; 94: 587-92
505. Morley BJ, Rodriguez-Sierra JF. A phenotype for the alpha 7 nicotinic acetylcholine receptor null mutant. Brain Res 2004; 1023: 41-7
506. Young JW, Crawford N, Kelly JS, et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 2007; 17: 145-55
507. Eells JB, Lipska BK, Young SK, et al. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res 2002; 136: 267-75
508. Rojas P, Joodmardi E, Hong Y, et al. Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry 2007; 12: 756-66
509. Eells JB, Misler JA, Nikodem VM. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice. Neuroscience 2006; 140: 1117-26
510. Devon RS, Anderson S, Teague PW, et al. The genomic organization of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 2001; 6: 311-4
511. Ohnuma T, Augood SJ, Arai K. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998; 56: 207-17
512. Henry SA, Lehmann-Masten V, Gasparini F, et al. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002; 43: 1199-209
513. Homayoun H, Stefani MR, Adams BW. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004; 29: 1259-69
514. Pietraszek M, Gravius A, Schäfer D, et al. MGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005; 49: 73-85
515. Brody SA, Conquet F, Geyer MA. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 2004; 172: 187-95
516. Kinney GG, Burno M, Campbell, UC. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 2003; 306: 116-23
517. Lipina T, Weiss K, Roder J. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology 2006; 32: 745-56
518. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4: 873-4
519. Ango F, Robbe D, Tu JC, et al. Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons. Mol Cell Neurosci 2002; 20: 323-9
520. Lominac KD, Oleson EB, Pava M. Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. J Neurosci 2005; 24: 11586-94
521. Kammermeier PJ, Worley PF. Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc Natl Acad Sci USA 2007; 104: 6055-60
522. Szumlinski KK, Lominac KD, Kleschen MJ. Behavioral and neurochemical phenotyping of Homer1mutant mice: possible relevance to schizophrenia. Genes Brain Behav 2005; 4: 273-88
523. Korostishevsky M, Kaganovich M, Cholostoy A, et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004; 56: 169-76
524. Boks MP, Rietkerk T, van de Beck MH, et al. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol 2007; 17: 567-72
525. Torrey EF, Barci BM, Webster MJ, et al. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57: 252-60
526. Volk DW, Austin MC, Pierri JN, et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57: 237-45